solute carrier family 10 member 1Genealiases: FHCA2 · NTCP
Q-omics provides the consensus-scored SLC10A1 profile across patient tissues and cancer cell-line models. SLC10A1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, SLC10A1 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, SLC10A1 RNA expression shows 16,530 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BLCA, COAD, and UVM as cancer lineages where SLC10A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC10A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC10A1 survival associations across molecular data types. SLC10A1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC10A1 RNA expression–survival associations across cancer types. High SLC10A1 expression shows unfavorable associations in BLCA, UVM and CHOL, but favorable associations in HNSC, LIHC and PAAD. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for SLC10A1 RNA expression.
This table summarizes SLC10A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC10A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC10A1 shows lower tumor expression in COAD, THCA, LIHC, CHOL, BRCA and LUAD. The COAD box plot shows higher SLC10A1 RNA expression in normal versus tumor tissue (log2 FC = −0.301, t-test p < 0.001).
This table shows molecular features associated with SLC10A1 in patient tissues and cancer cell lines. In patient samples, SLC10A1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC10A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and SOFT_TISSUE.
